Friedrich G, Braunstein P, Friedrich M, Vach W
Institut für Rechtsmedizin, Universität Freiburg.
Beitr Gerichtl Med. 1991;49:111-9.
In the capacity of an initial study both, the pharmacocinetics as well as the metabolism of etorphine were investigated. In a self-trial a bolus of 8 micrograms tritium-marked etorphine as administered intravenously and subsequently the half-lives in serum and urine were determined. To achieve this, etorphine and etorphineclucuronide were separated via HPLC and then quantified by measuring the radioactivity. The development of the concentrations was devided into 3 phases. Within the first phase half-lives of etorphine and etorphineglucuronide were found in the range of 0.3-1 hour in serum and, likewise, in urine. During the second phase the estimated half-life of etorphineglucuronide was 160-260 hours in serum as well as in urine. Within the last phase half-lives in urine were 47 hours for etorphine and 41 hours for etorphineglucuronide while the calculation of the half-lives in serum was not sufficiently feasible.
作为一项初步研究,对埃托啡的药代动力学和代谢情况进行了调查。在一项自身试验中,静脉注射了8微克氚标记的埃托啡推注剂量,随后测定了其在血清和尿液中的半衰期。为此,通过高效液相色谱法分离出埃托啡和埃托啡葡糖醛酸化物,然后通过测量放射性进行定量。浓度变化分为3个阶段。在第一阶段,血清和尿液中埃托啡和埃托啡葡糖醛酸化物的半衰期在0.3 - 1小时范围内。在第二阶段,血清和尿液中埃托啡葡糖醛酸化物的估计半衰期为160 - 260小时。在最后阶段,尿液中埃托啡的半衰期为47小时,埃托啡葡糖醛酸化物的半衰期为41小时,而血清中半衰期的计算不太可行。